Business Wire

AGCO Agriculture Foundation to Donate BRL 240,000 to Amigos do Bem institution

3.8.2023 17:02:00 EEST | Business Wire | Press release

Share

The AGCO Agriculture Foundation (the “Foundation”), a private foundation with the vision to prevent and relieve hunger through sustainable agriculture development, will donate BRL 240,000 ($50,000) to Amigos do Bem. The resources will support the “Cashew Project: Transformation Seedlings”, which aims to develop small cashew farmers in the northeast of Brazil, generating work and income and positively impacting extremely vulnerable families.

The donation from the Foundation will be used to purchase and distribute 30,000 fruit tree seedlings, fertilizers and farming kits, as well as provide training, technical support and continuous monitoring of small farmers in the northeast of Brazil. The initiative will support 100 families, reaching more than 500 people directly and indirectly, in addition to supporting the neutralization of 500 tons of CO2 per year with the planting of cashew trees.

“The cashew seedling initiative directly and positively impacts small producers and the environment. Most importantly, it builds a pathway into a guaranteed market for their crops," said Roger Batkin, Chair of the Foundation. “This type of social impact initiative is strongly aligned with the Foundation’s approach for impactful programs that support food security and sustainable agricultural development in rural communities.”

The cashew seedlings to be distributed to farmers will be planted on their own land, with a guaranteed purchase of products at market value, encouraging the role of Brazilian nut suppliers and generating direct and indirect income opportunities.

“By supporting the initiative, we will contribute to transforming the lives of small farmers and their families in the northeastern hinterland, strengthening local agricultural development in a sustainable way and promoting the autonomy and empowerment of these communities,” emphasizes Rodrigo Junqueira, Vice President Massey Ferguson and General Manager South America.

Created in 1993, the nonprofit institution Amigos do Bem promotes continuous education, job and income generation projects and access to water, housing, and health. The social project regularly aids 150,000 people throughout the northeast region of Brazil, with a focus on eradicating extreme poverty. "The Cashew Project started in 2018, with the distribution of surplus seedlings from our own plantations so that small-scale producers could find a source of income and subsistence. It ended up revolutionizing the cashew nut chain in the region," comments André de Luca, Executive Director at Amigos do Bem.

For the next five years, Amigos do Bem project goal is to neutralize 2,300 tons of carbon by planting 150,000 cashew trees, in addition to reaching around 420 farmers, generating income for their families.

About AGCO

AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Fendt®, GSI®, Massey Ferguson®, Precision Planting® and Valtra®. Powered by Fuse® smart farming solutions, AGCO’s full line of equipment and services help farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $12.7 billion in 2022. For more information, visit www.AGCOcorp.com. For company news, information, and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.

About AGCO Agriculture Foundation

Founded by AGCO Corporation (NYSE: AGCO) in 2018, the AGCO Agriculture Foundation is a private foundation with the vision to prevent and relieve hunger. The Foundation promotes impact programs that support food security, sustainable agricultural development and build the necessary agricultural infrastructure in marginalized farming communities. The Foundation is domiciled in Vaduz, Liechtenstein and its operations are managed from Duluth, Georgia, USA. For more information, visit https://www.agcofoundation.org/.

About the NGO Amigos do Bem

For 30 years, the Amigos do Bem institution has been working to transform lives in the northeastern hinterland, the poorest and most isolated region in Brazil. Every month, 150,000 people, who live in 300 villages in extreme poverty, are assisted with ongoing projects in education, work and income, water, housing, and health. We promote social inclusion and local development, meeting 12 of the 17 UN Sustainable Development Goals. We created a Sustainable Social Development Model and several initiatives with a positive impact with the participation of almost 11,000 volunteers. For more information, visit https://www.amigosdobem.org/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aryn Drawdy, Corporate Communications Director
Aryn.Drawdy@agcocorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 15:51:00 EEST | Press release

vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports enamel repair by facilitating the formation of crystalline mineral structure throughout the affected area, giving dental professionals an easy-to-use, restorative opti

IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 15:30:00 EEST | Press release

Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to double down on connected TV, the need for greater visibility and performance insight has never been more important,” said Dana McGraw, SVP, Data and Measurement Science, Disney Advertising. “By collaborating with IAS, we’re helping provide advertisers with clearer

Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 15:00:00 EEST | Press release

Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-making. However, compared to Riskified’s agentic commerce pulse survey in Q4 2025, consumer sentiment has shifted, with growing concerns around fraud, security, and accountability slowing the path to fully autonomous, agent-driven transactions. Key findings from th

Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 15:00:00 EEST | Press release

Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environment. The findings highlight a growing disconnect between ambition and execution. Cross-border transactions are expected to form a significant portion of deal pipelines, with 47% of respondents expecting them to account for between 26% and

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼ REZZAYO ® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 14:43:00 EEST | Press release

Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing allogeneic HSCT face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis,1 representing a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable efficacy is expected. The ReSPECT study met its primary endpoint for US Food and Drug Administration (FDA) and European Medicines

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye